GlaxoSmithKline signed a potential $1 billion deal with U.S. biotech company Concert Pharmaceuticals to develop drugs that use deuterium, a chemical that could improve how some medicines work. The collaboration will beef up GlaxoSmithKline's pipeline of early stage drugs.